Market capitalization | SEK12.35b |
Enterprise Value | SEK12.41b |
P/E (TTM) P/E ratio | 48.41 |
EV/FCF (TTM) EV/FCF | 37.83 |
EV/Sales (TTM) EV/Sales | 5.86 |
P/S ratio (TTM) P/S ratio | 5.83 |
P/B ratio (TTM) P/B ratio | 3.27 |
Dividend yield | 1.03% |
Last dividend (FY23) | SEK1.60 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a Biotage AB forecast:
5 Analysts have issued a Biotage AB forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,117 2,117 |
32%
32%
|
|
Gross Profit | 1,323 1,323 |
35%
35%
|
|
EBITDA | 573 573 |
55%
55%
|
EBIT (Operating Income) EBIT | 393 393 |
65%
65%
|
Net Profit | 257 257 |
36%
36%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biotage AB engages in the provision of separation and synthesis technology solutions. Its products and services include sample preparation, horizon food and environmental products, organic synthesis, peptide chemistry, flash purification, work-up products, evaporation and concentration, and service and support. The company was founded by Pal Nyren, Carl Erik Mathias Uhlen, Mostafa Ronaghi, Bertil Pettersson, Neil Goldsmith and Bjorn Ekstrom in 1969 and is headquartered in Uppsala, Sweden.
Head office | Sweden |
CEO | Frederic Vanderhaegen |
Employees | 674 |
Founded | 1997 |
Website | www.biotage.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.